Edaravone is a novel free radical scavenger that exerts neuroprotective effects by inhibiting endothelial injury and by ameliorating neuronal damage in brain ischemia. Recently, it was reported that edaravone could alleviate the pathology and cognitive deficits of Alzheimer's disease patients. However, its relevance to vascular dementia (VaD) is not clear. In this study, we partially occluded the bilateral carotid arteries of rats surgically to induce chronic cerebral hypoperfusion (CCH), a well-known rat model of VaD. Water maze and step-down inhibitory test were used to evaluate the memory deficit. The activities of superoxide dismutase (SOD) and lactate dehydrogenase (LDH), the content of malondialdehyde (MDA) and total reactive oxygen species were measured to evaluate the oxidative stress level. Western blot analysis was used to evaluate the synaptic protein expression. It was found that treatment with edaravone for a 5-week period was able to reverse both spatial and fear-memory deficits in rats with CCH. Edaravone significantly reduced the level of oxidative stress in the brains of rats with CCH by increasing SOD activity and decreasing the content of MDA, LDH, and total reactive oxygen species. Furthermore, edaravone treatment also restored the levels of multiple synaptic proteins in the hippocampi of rats with CCH. Our data provide direct evidence supporting the neuroprotective effects of edaravone in VaD. We propose that the alleviation of oxidative stress and restoration of synaptic proteins play important roles in neuroprotection.
Introduction
Vascular dementia (VaD) is a term usually reserved for subtly progressive impairments of memory and other cognitive functions that are presumed to be due to vascular disorders within the brain. Although patients with VaD often present symptoms similar to those with Alzheimer's disease (AD), the related changes in the brain of VaD patients are not attributed to AD pathology but to a chronic reduction in blood flow within the brain. VaD is the second most common form of dementia after AD in older adults [1] . In a previous meta-analysis of European studies on dementia incidence, it was shown that VaD constituted 17.6% of all dementias [2] . In China and Japan, VaD accounts for almost 50% of all dementia [3] and is referred to as the 'silent epidemic of the twenty-first century' [1] . It is known that the major cause of VaD is chronic cerebral hypoperfusion (CCH) that is resulted from multiple disorders of the cerebral vascular system, including hypertension, diabetes, generalized atherosclerosis, and smoking [4, 5] . Previous reports have shown that CCH leads to neurodegeneration by a reduction in neuronal energy, and the production of reactive oxygen species and proinflammatory cytokines via abnormal activation of microglial cells. These in turn impair the function of neuronal cells and contribute to brain lesions and cognitive decline [6] [7] [8] . Thus, CCH is critical in the pathogenesis of VaD, and CCH induced by permanent occlusion of the bilateral carotid arteries has been widely used as a model for VaD [9] .
Edaravone, 3-methyl-1-phenyl-2-pyrazoline-5-one, is a nootropic and neuroprotective agent used for the purpose of aiding neurological recovery following acute brain ischemia and subsequent cerebral infarction [10] . It is the first neuroprotective agent approved for clinical use in Japan in 2001. In a Japanese multicenter, randomized clinical trial, edaravone was found to significantly reduce brain-infarct volume and produce sustained improvements in functional outcomes during a 12-month follow-up [11] . Edaravone also displays neuroprotective effects by inhibiting vascular endothelial cell injury and ameliorating neuronal damage in ischemic brain models [12] . Recently, the application of edaravone in a mouse model of AD was demonstrated to reduce amyloid pathology and rescue memory deficits [13] . Thus, edaravone is predicted to have protective effects on neurological disorders with memory impairments.
In this study, we found that long-term treatment of rats with edaravone for 5 weeks restored both the spatial and fear-memory impairments caused by CCH. We also found that edaravone treatment significantly reduced oxidative stress and rescued multiple important synaptic proteins in the hippocampus.
Materials and Methods

Drugs and antibodies
Edaravone and DCFH-DA (used to detect ROS content) were purchased from Sigma (St Louis, USA). The malondialdehyde assay kit, superoxide dismutase (SOD) assay kit, and lactate dehydrogenase assay kit were purchased from Nanjing Built Technology Co. (Nanjing, China). Polyclonal antibodies (pAb) PSD95 (1:1000) against PSD95 protein, pAb PSD93 (1:1000) against PSD93 protein, and pAb NR2B against N-methyl-D-aspartate receptor (NMDA) 2B (1:500) were purchased from Bioworld Technology Inc. (St Louis Park, USA). The pAb phosphorylated cAMP-response element binding protein (p-CREB) against phosphorylated CREB at the Ser133 site (1:1000) and total CREB (t-CREB) against total CREB (1:1000) were purchased from Santa Cruz Biotechnology (Santa Cruz, USA). The pAb IRDye 800CW-conjugated goat (polyclonal) anti-rabbit IgG (1:10,000) and IRDye 800CW-conjugated goat (polyclonal) anti-mouse IgG (1:10,000) were purchased from LI-COR Biosciences (Lincoln, USA).
Animals
Sixty male Wistar rats (bodyweight: 220 ± 10 g) were purchased from Henan Provincial Disease Prevention and Control Center (Zhengzhou, China). All animal experimental protocols were approved by the Laboratory Animals Research Center of Henan Province in accordance with guidelines for the Care and Use of Laboratory Animals and Henan Province Regulations for the Administration of Laboratory Animals. The animals were acclimated to the animal facility for 5 days after arrival. Then they were randomly divided into four groups: a sham group (sham, 0.9% NaCl, i.p. n = 15), a cerebral hypoperfusion group (CCH, n = 15), a cerebral hypoperfusion group with edaravone (5 mg/kg, i.p.) treatment for 4 weeks after surgery (CCH + Edaravone, n = 15), and a sham with edaravone treatment group (Edaravone, 5 mg/kg, i.p. n = 15). All rats were housed in polypropylene cages in a vivarium at room temperature, under a 12/12-h light/dark cycle (lights on at 8:00 am), with free access to food and water.
Chronic cerebral hypoperfusion
CCH was induced by bilateral common carotid artery stenosis as previously described [14] . Briefly, rats were anesthetized with 10% chloral hydrate (350 mg/kg, i.p.) and the skulls were fully exposed. The bilateral common carotid arteries were exposed and freed from the surrounding connective tissue through a midline cervical incision. For hypoperfusion, metal coils (180 μm inner diameter; Sawane Spring Company, Hamamatsu, Japan) were positioned to encircle the common carotid arteries, reducing blood flow to~70%. To analyze the cerebral blood flow (CBF), a solution of yellowgreen fluospheres (15 ± 0.5 μm diameter, 1,000,000 fluorescent microspheres/ml; Molecular Probes, Waltham, USA) was sonicated, vortexed, and injected (injection volume: 100 μl) into the left ventricle of 12-instrumented anesthetized rats with a syringe, then a laser-Doppler flowmetry was used to assay the blood flow [14, 15] . All muscles and glands were guided back into place, the incision was sutured, and the local anesthetic was applied to the wound before recovery. The procedures were accomplished within 15 min. During surgery, the body temperature of the rats was monitored and maintained at 37.5 ± 0.5°C by means of a heating lamp until the rats recovered to thermal homeostasis. Four weeks after surgery, the behavioral tasks were carried out every day at 9:00 am.
Morris water maze test
The Morris water maze test was used to assess the spatial memory of animals [16] . The maze was a circular pool with a diameter of 150 cm and a height of 50 cm. It was divided into four imaginary quadrants and filled with water at the temperature of 20-21°C. Briefly, rats were trained over 5 days to find a platform in the SW quadrant that was submerged in 1-2 cm of water, using a stationary array of cues positioned outside the pool. In each trial, rats were given a maximum time of 60 s to find the hidden platform and were allowed to remain on it for 30 s. Acquisition training consisted of a total of 20 trials, with four spaced trials per day for five consecutive days. After a one-day rest, a test was conducted. The latency to reach the platform zone and the swimming pathways to find the hidden platform were recorded in all training trials and in the test by the commercial software ANYmaze system (Stoelting, Wood Dale, USA).
Step-down inhibitory avoidance test
The step-down inhibitory avoidance test was used to assess the emotional cognition of rats. The test procedures were similar to those previously reported [17] . Briefly, the experimental device STT-2 (Chinese Academy of Medical Sciences, Beijing, China) comprised five chambers of equal size (11 cm × 11 cm × 30 cm) which were made of Plexiglas in three sides and black plastic in one side. The grid-shape bottom of each chamber consisted of 12 parallel steel bars (diameter 0.4 cm), with a 0.6 cm space between adjacent bars. A rubber platform (height 3 cm, diameter 3 cm) was glued to the bottom of the chamber in one corner to provide a shelter from the electric shock. During the training period, the rats were allowed in the chamber for 5 min to eliminate the exploratory response, and then exposed to a scrambled foot shock (0.4 mA for 3 min) from the steel grid. The number of times that rats stepped down from the platform in 3 min (the number of errors) was recorded as an indicator. After 48 h of rest, rats were placed directly on the platform and the steel grid was electrified. The latency period until the first step-down from the platform (step-down latency) and the number of errors were recorded.
Assays of oxidative damage
After the behavioral test, six rats from each group were selected randomly and sacrificed. Their brains were quickly removed, and the hippocampi were dissected on ice and ground into 10% tissue homogenates with 0.1 M PBS buffer solution (pH 7.4). The tissue homogenates were centrifuged at 10,000 g for 10 min at 4°C, and the supernatants were collected and prepared for the measurement of SOD activity, MDA content, and LDH level according to the manufacturer's instructions. The ROS content was measured using the dichlorofluorescein method as described previously [17] .
Western blot analysis
After behavioral tests, six rats from each group were used to measure the levels of memory-associated proteins in the hippocampus. Rats were sacrificed, and the hippocampi were removed and homogenized in a buffer containing 10 mM Tris-Cl (pH 7.6), 50 mM NaF, 1 mM Na 3 VO 4 , 1 mM edetic acid, 1 mM benzamidine, and 1 mM phenylmethanesulfonyl fluoride. After measuring the protein concentration in the supernatant of each homogenate using a bicinchoninic acid assay kit, a final concentration of 5% β-mercaptoethanol and 0.05% bromophenol blue were added, and the samples were boiled for 10 min. Equal amounts of proteins were separated by SDSpolyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. The membranes were blocked in 5% nonfat milk and probed overnight at 4°C with the following antibodies: anti-NR2B, anti-PSD95, anti-PSD93, anti-p-CREB, anti-t-CREB, and anti-β-actin. The membranes were washed three times, and then incubated with the corresponding secondary antibody for 2 h at room temperature, washed and visualized using the Odyssey Infrared Imaging System. Protein bands were quantitatively analyzed by Kodak Digital Science 1D software (Eastman Kodak Company, New Haven, USA).
Statistical analysis
All statistical analyses were conducted using SPSS version 16.0. Group differences in the escape latency in the Morris water maze task were analyzed using two-way analysis of variance (ANOVA) with repeated measures, the factors being group and time. Otherwise, data were analyzed by one-way ANOVA followed by the Student-Newman-Keuls test as a post hoc test. Significance was set at P < 0.05 for all tests.
Results
Edaravone reverses CCH-induced spatial memory impairments
To investigate the effects of edaravone on CCH-induced cognitive impairment, the spatial learning and memory abilities of rats were first evaluated with the Morris water maze task. The swimming traces of the rats showed that the sham rats reached the platform in <20 s using a direct searching strategy, while the CCH rats took over 40 s using a random searching strategy (Fig. 1A) . It was also found that the escape latency decreased significantly during training [F(4,18) = 10.8, P < 0.01] and there was a significant difference among the four groups [F(3,48) = 13.39, P < 0.01]. On the first 2 days, there was no significant difference among the groups. From Day 3, the escape latency of the CCH group was longer than that of the sham group (n = 12, P < 0.05), and that of the CCH + Edaravone group was also significantly decreased compared with the CCH group (n = 12, P < 0.05), but there was no significant difference between the sham and Edaravone groups (P > 0.05; Fig. 1B ). In the test period, rats in the CCH group spent more time trying to find the platform than the sham group (n = 12, P < 0.05) and edaravone treatment improved the performance of CCH + Edaravone rats (n = 12, P < 0.05), while there was no obvious difference between the sham and Edaravone groups (P > 0.05, Fig. 1C) . Throughout the tasks, the swimming speed of the rats did not show any obvious differences (Fig. 1D) .
Edaravone reverses CCH-induced fear-memory impairments
The step-down inhibitory avoidance test was used to evaluate the emotional cognition of the rats. The step-down latency of the rats did not show significant differences among the groups during training. During the test period, CCH rats showed obviously shorter latency than control rats, and edaravone improved the performance of CCH rats (P < 0.05, Fig. 2A ). Rats in CCH group made more errors both in the training and test periods (P < 0.05, respectively), and edaravone reduced the number of errors (P < 0.05, Fig. 2B ). There were no significant differences between the sham and Edaravone groups.
Edaravone attenuates CCH-induced oxidative stress
Edaravone has been used as a scavenger of oxidants, so the levels of markers for oxidative stress were then measured in the brains of rats in vivo. As shown in Fig. 3 , the SOD activity, and levels of MDA, LDH, and ROS were much higher in the CCH group than in the controls (P < 0.01, respectively), and edaravone reduced the increase in these oxidative markers that accompanied hypoperfusion. However, there was no significant change in CBF between CCHand CCH plus edaravone-treated rats ( Supplementary Fig. S1 ).
Edaravone attenuates CCH-induced loss of synaptic proteins
Because edaravone treatment altered the memory function of rats, we speculated that the expression of some synaptic proteins might also be changed. By examining the protein levels of the NMDA receptor 2 A/B (NR2A/B), PSD95, and PSD93 in the hippocampus, we found that that the levels of PSD95, NR2A/B, and PSD93 were significantly decreased after CCH (P < 0.01, respectively), and were partially improved by the administration of edaravone (P < 0.01, Fig. 4A,B) . Figure 4C ,D showed the level of the upstream transcription factor, CREB, which regulate these synaptic proteins. It was found that the ratio of p-CREB (the activated form) to t-CREB in the hippocampus was increased significantly in the CCH group (P < 0.01), and decreased after edaravone treatment (P < 0.01).
Discussion
In this study, we reported that treatment with edaravone for a 5-week period was able to reverse both spatial and fear-memory deficits in rats with CCH, which provides a direct in vivo evidence supporting the possible use of edaravone for memory preservation in CCH-related dementia. As described above, application of edaravone in a mouse model of AD effectively reduced amyloid pathology and rescued memory deficits [13] , our data here further extend the neuroprotective role of edaravone in memory impairment.
Oxidative stress refers to an environment where the imbalance between pro-oxidant and antioxidant species favors the former [18, 19] . Cerebral ischemia has been recognized as a risk factor for VaD and is highly correlated with increased free-radical production. An elevation of MDA levels has been found in blood samples from patients with VaD when compared with aged-matched control subjects [20] . In addition, the levels of markers of oxidative DNA damage, such as 8-oxo-2'-deoxyguanosine and 8-oxoguanine, were also shown to be elevated in the cerebrospinal fluid and urine of VaD subjects [21] . Thus, those comparative studies measuring markers of oxidative stress and a range of enzymatic and non-enzymatic antioxidants indicate a critical role for ROS in VaD pathology. Consequently, suppressing oxidative stress might be a potential therapy for VaD. Edaravone was first used as a free radical scavenger and was shown to be neuroprotective against ischemic stroke clinically [10] . In many studies, edaravone has been shown to decrease oxidative stress [22] , protect the neurovascular unit [23, 24] , and reduce the activation of microglia after ischemic stress [12] . It has been suggested that edaravone can quench hydroxyl radicals (·OH) and peroxynitrite (ONOO − ), and has inhibitory effects on both water-soluble and lipid-soluble peroxyl radicals (LOO·) [25] . Thus, this compound exerts a wide range of antioxidant effects on ROS beyond those of water-soluble or lipid-soluble antioxidant vitamins [24] . In a previous study, edaravone was found to have anti-oxidative stress and anti-inflammatory effects in postoperative cognitive dysfunction induced by surgery plus lipopolysaccharide administration [26] . In this study, we found that long-term treatment with edaravone restored SOD activity and reduced the levels of MDA, LDH, and ROS in CCH rats. These findings further verified a neuroprotective role of edaravone in memory deficits, especially in cerebral ischemia and related disorders induced memory deficits. Oxidative stress in the brain induces dysfunction of the nervous system, including memory loss. We also found that the inhibitory effects of edaravone on oxidative stress were able to reduce memory deficits in CCH rats. However, CBF was not restored after edaravone treatment, indicating that the beneficial effect of edaravone is through the direct effect in the hippocampus rather than through the indirect effect in the constriction sites in the carotid artery.
Synapses and the loss of synaptic proteins play an important role in AD-type dementias [27, 28] , as well as in non-Alzheimer's dementias which occur independently of the formation of amyloid-β plaques. In VaD, the synaptophysin immunoreactivity of the cortical neuropil is reduced, similar to that in AD [29, 30] . In another study, a significant reduction in presynaptic proteins (including a significant reduction in SNAP-25) was reported in the temporal cortex of patients with VaD [31] . In our study, we found that the protein levels of NR2A/B, PSD95, PSD93, and phosphorylated CREB were reduced in CCH rats, suggesting the loss of those synaptic proteins. It is known that NMDA receptors are the dominant postsynaptic glutamate receptors mediating synaptic plasticity [32] , and PSD93 [33] and PSD95 [34] are key components of the postsynaptic membrane. Phosphorylation of CREB at Ser133 is thought to be crucial to the memory process. As edaravone was shown to upregulate the activity of Akt [26] , which is able to increase the phosphorylation of CREB at Ser133 site [35] , we predicted that Akt activation might play an important role in the protection of edaravone on synaptic proteins. Thus, the rescue of those synaptic proteins by edaravone treatment might preserve synaptic function in CCH rats and alleviate memory deficits.
In summary, our data suggest that edaravone treatment is able to curtail memory impairments, inhibit oxidative stress, and restore synaptic proteins in CCH rats. 
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